Clinical Trial Update: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) [Phase 2]

View source ↗

Summary

Phase 2 SURPASS-2 trial evaluating ADP-A2M4CD8 in HLA-A2+ patients with MAGE-A4 positive esophageal or esophagogastric junction cancers was terminated; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophagogastric Junction Cancer

Drugs mentioned

• ADP-A2M4CD8

Snippet

Sponsor: Adaptimmune | Conditions: Esophageal Cancer, Esophagogastric Junction Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-09-04